Timber Pharmaceuticals, Inc.
https://www.biopharmx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Timber Pharmaceuticals, Inc.
Leo’s New Growth Driver Anzupgo Poised For EU Approval
The JAK inhibitor cream for hand eczema will serve a large market in Europe and help the Danish dermatology specialist expand its strong position in dermatology.
Leo Looks For More Deals After Sealing Timber Buy
The Danish group’s pursuit of Timber, and its late-stage congenital ichthyosis therapy, has finally reached a successful conclusion and CEO Christophe Bourdon tells Scrip that the search is on for more innovative assets.
Deal Watch: Leo Pharma Adds Rare Dermatology Disorder Candidate In Timber Buyout
Plus deals involving SK Biopharmaceuticals, Hikma and Proteovant, Day One/Sprint, Eyenovia/Formosa, Clinigen/CNX, Ikena/Pionyr and more.
Keeping Track: US FDA Clears New Uses For Incyte’s Pemazyre, AbbVie’s Imbruvica; Minerva Seeks First Negative Symptoms Claim In Schizophrenia
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
-
Drug Delivery
- Topical Delivery
-
Drug Delivery
- Other Names / Subsidiaries
-
- BioPharmX Corporation, Inc.
- Timber Pharmaceuticals LLC
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice